Citius Oncology closes $9 million equity offering

Citius Oncology Inc. (NASDAQ: CTOR) completed a registered direct offering and concurrent private placement raising approximately $9 million in gross proceeds, the company announced in a press release.

The oncology-focused subsidiary of Citius Pharmaceuticals Inc. (NASDAQ: CTXR) sold 5,142,858 shares of common stock and accompanying warrants at a combined price of $1.75 per share. The warrants carry an exercise price of $1.84 per share and will be exercisable six months from issuance, expiring five and one-half years from the date of issuance.

Maxim Group LLC served as the sole placement agent for the transaction. The common stock was offered under a Form S-3 registration statement filed with the Securities and Exchange Commission on September 2, 2025, and declared effective September 4, 2025.

The warrants and shares issuable upon their exercise were offered through a private placement under Section 4(a)(2) of the Securities Act of 1933 and have not been registered under federal securities laws.

Citius Oncology received FDA approval in August 2024 for its primary asset LYMPHIR, a treatment for adults with relapsed or refractory cutaneous T-cell lymphoma who have had at least one prior systemic therapy. Citius Pharmaceuticals owns 79% of Citius Oncology.

You May Also Be Interested In